Literature DB >> 25852560

A new classifier-based strategy for in-silico ion-channel cardiac drug safety assessment.

Hitesh B Mistry1, Mark R Davies2, Giovanni Y Di Veroli3.   

Abstract

There is currently a strong interest in using high-throughput in-vitro ion-channel screening data to make predictions regarding the cardiac toxicity potential of a new compound in both animal and human studies. A recent FDA think tank encourages the use of biophysical mathematical models of cardiac myocytes for this prediction task. However, it remains unclear whether this approach is the most appropriate. Here we examine five literature data-sets that have been used to support the use of four different biophysical models and one statistical model for predicting cardiac toxicity in numerous species using various endpoints. We propose a simple model that represents the balance between repolarisation and depolarisation forces and compare the predictive power of the model against the original results (leave-one-out cross-validation). Our model showed equivalent performance when compared to the four biophysical models and one statistical model. We therefore conclude that this approach should be further investigated in the context of early cardiac safety screening when in-vitro potency data is generated.

Entities:  

Keywords:  biostatistics; cardiac toxicity; ion-channel pharmacology; mathematical model; predictive pharmacology

Year:  2015        PMID: 25852560      PMCID: PMC4371651          DOI: 10.3389/fphar.2015.00059

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  17 in total

1.  Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium.

Authors:  Philip T Sager; Gary Gintant; J Rick Turner; Syril Pettit; Norman Stockbridge
Journal:  Am Heart J       Date:  2013-12-02       Impact factor: 4.749

Review 2.  Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative.

Authors:  Icilio Cavero; Henry Holzgrefe
Journal:  Expert Opin Drug Saf       Date:  2014-06       Impact factor: 4.250

3.  An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment.

Authors:  M R Davies; H B Mistry; L Hussein; C E Pollard; J-P Valentin; J Swinton; N Abi-Gerges
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-12-23       Impact factor: 4.733

Review 4.  Whole-heart modeling: applications to cardiac electrophysiology and electromechanics.

Authors:  Natalia A Trayanova
Journal:  Circ Res       Date:  2011-01-07       Impact factor: 17.367

5.  Inherited arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function.

Authors:  Stephan E Lehnart; Michael J Ackerman; D Woodrow Benson; Ramon Brugada; Colleen E Clancy; J Kevin Donahue; Alfred L George; Augustus O Grant; Stephen C Groft; Craig T January; David A Lathrop; W Jonathan Lederer; Jonathan C Makielski; Peter J Mohler; Arthur Moss; Jeanne M Nerbonne; Timothy M Olson; Dennis A Przywara; Jeffrey A Towbin; Lan-Hsiang Wang; Andrew R Marks
Journal:  Circulation       Date:  2007-11-13       Impact factor: 29.690

6.  A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).

Authors:  Hua Rong Lu; Gan-Xin Yan; David J Gallacher
Journal:  J Pharmacol Toxicol Methods       Date:  2013-01-19       Impact factor: 1.950

7.  hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment.

Authors:  Giovanni Y DI Veroli; Mark R Davies; Henggui Zhang; Najah Abi-Gerges; Mark R Boyett
Journal:  J Cardiovasc Electrophysiol       Date:  2013-10-07

8.  Universally sloppy parameter sensitivities in systems biology models.

Authors:  Ryan N Gutenkunst; Joshua J Waterfall; Fergal P Casey; Kevin S Brown; Christopher R Myers; James P Sethna
Journal:  PLoS Comput Biol       Date:  2007-08-15       Impact factor: 4.475

9.  Prediction of Thorough QT study results using action potential simulations based on ion channel screens.

Authors:  Gary R Mirams; Mark R Davies; Stephen J Brough; Matthew H Bridgland-Taylor; Yi Cui; David J Gavaghan; Najah Abi-Gerges
Journal:  J Pharmacol Toxicol Methods       Date:  2014-07-31       Impact factor: 1.950

10.  Evaluation of an in silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge.

Authors:  Kylie A Beattie; Chris Luscombe; Geoff Williams; Jordi Munoz-Muriedas; David J Gavaghan; Yi Cui; Gary R Mirams
Journal:  J Pharmacol Toxicol Methods       Date:  2013-04-25       Impact factor: 1.950

View more
  13 in total

Review 1.  Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes.

Authors:  Elin Nyman; Yvonne J W Rozendaal; Gabriel Helmlinger; Bengt Hamrén; Maria C Kjellsson; Peter Strålfors; Natal A W van Riel; Peter Gennemark; Gunnar Cedersund
Journal:  Interface Focus       Date:  2016-04-06       Impact factor: 3.906

2.  In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers.

Authors:  Chuipu Cai; Jiansong Fang; Pengfei Guo; Qi Wang; Huixiao Hong; Javid Moslehi; Feixiong Cheng
Journal:  J Chem Inf Model       Date:  2018-05-10       Impact factor: 4.956

Review 3.  Recent developments in using mechanistic cardiac modelling for drug safety evaluation.

Authors:  Mark R Davies; Ken Wang; Gary R Mirams; Antonello Caruso; Denis Noble; Antje Walz; Thierry Lavé; Franz Schuler; Thomas Singer; Liudmila Polonchuk
Journal:  Drug Discov Today       Date:  2016-02-15       Impact factor: 7.851

4.  Global Optimization of Ventricular Myocyte Model to Multi-Variable Objective Improves Predictions of Drug-Induced Torsades de Pointes.

Authors:  Trine Krogh-Madsen; Anna F Jacobson; Francis A Ortega; David J Christini
Journal:  Front Physiol       Date:  2017-12-19       Impact factor: 4.566

5.  Mechanistic Systems Modeling to Improve Understanding and Prediction of Cardiotoxicity Caused by Targeted Cancer Therapeutics.

Authors:  Jaehee V Shim; Bryan Chun; Johan G C van Hasselt; Marc R Birtwistle; Jeffrey J Saucerman; Eric A Sobie
Journal:  Front Physiol       Date:  2017-09-08       Impact factor: 4.566

6.  Complex versus simple models: ion-channel cardiac toxicity prediction.

Authors:  Hitesh B Mistry
Journal:  PeerJ       Date:  2018-02-05       Impact factor: 2.984

7.  Novel Two-Step Classifier for Torsades de Pointes Risk Stratification from Direct Features.

Authors:  Jaimit Parikh; Viatcheslav Gurev; John J Rice
Journal:  Front Pharmacol       Date:  2017-11-14       Impact factor: 5.810

8.  Global Sensitivity Analysis of Ventricular Myocyte Model-Derived Metrics for Proarrhythmic Risk Assessment.

Authors:  Jaimit Parikh; Paolo Di Achille; James Kozloski; Viatcheslav Gurev
Journal:  Front Pharmacol       Date:  2019-10-02       Impact factor: 5.810

9.  Classifying Drugs by their Arrhythmogenic Risk Using Machine Learning.

Authors:  Francisco Sahli-Costabal; Kinya Seo; Euan Ashley; Ellen Kuhl
Journal:  Biophys J       Date:  2020-01-22       Impact factor: 4.033

10.  Usefulness of Bnet, a Simple Linear Metric in Discerning Torsades De Pointes Risks in 28 CiPA Drugs.

Authors:  Sungpil Han; Seunghoon Han; Ki-Suk Kim; Hyang-Ae Lee; Dong-Seok Yim
Journal:  Front Pharmacol       Date:  2019-11-26       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.